Clinical trials: BIS
End Stage Renal Failure on Dialysis
A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease
The optimal frequency of hemodialysis treatments in patients with incident end-stage kidney disease in not known. This pilot trial will randomize patients with incident end-stage kidney disease due to chronic kidney disease…
- Trial name
- TWOPLUS-HD (NCT03740048)
- Testing
- Hemodialysis, Patiromer Oral Product
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Emergence Agitation
The Effect of Depth of Anesthesia as Measured by Bispectral Index (BIS) on Emergence Agitation in Children
The purpose of this study is to determine whether depth of anesthesia has an effect on emergence agitation (EA) in children age 2 - 8 years old.
- Trial name
- NCT00990769
- Testing
- Depth of anesthesia
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Movement Disorders, Depth of Anesthesia Monitors
BIS and Entropy in Deep Brain Simulation
The main objective of the study is to determine whether depth of anesthesia (DOA) monitoring such as Bispectral Index (BIS) and entropy are accurate in patients with neuro-psychological conditions such as Parkinson's disease by…
- Trial name
- NCT02386995
- Testing
- BIS monitor, Entropy monitor
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Common Wart
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
- Trial name
- NCT03278028
- Testing
- A-101 Topical Solution, A-101 Vehicle Solution
- Where
- 16 sites in United States
- Volunteers
- 159 people
- Sponsor
- Aclaris Therapeutics, Inc.
Common Wart
A Study of A-101 Topical Solution for the Treatment of Common Warts
Phase 3 Study of A-101 Topical Solution in Subjects with Common Warts
- Trial name
- NCT03691831
- Testing
- Active, Vehicle
- Where
- 24 sites in United States
- Volunteers
- 502 people
- Sponsor
- Aclaris Therapeutics, Inc.